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ABSTRACT 
Rod-cone dystrophies (RCD) are a heterogeneous group of genetic retinal 
disorders characterized by the progressive loss of rod and cone photoreceptors, leading 
in most cases to severe visual impairment. It is one of the most common inherited 
diseases of the retina with a unique set of clinical characteristics that make it a complex 
disease associated to distinct inheritance patterns. 
Mutations in the rhodopsin gene (RHO) are suggested to be the most common 
cause of autosomal dominant retinitis pigmentosa (adRP); nevertheless, the prevalence 
of RHO mutations in the Portuguese population has not been established. In this study, 
direct cycle sequencing was used to analyze all five coding exons and adjacent intronic 
regions of the RHO gene in 48 Portuguese probands with different forms of non X-
linked RP (XLRP).  
Two novel RHO missense mutations were identified in 2 of the 48 unrelated 
tested probands; the c.180 T>C transition (exon 1) leading to a p.Y60H substitution, 
identified in patient AAV, is located at the cytoplasmic end of the first transmembrane 
domain, whereas the c.207 C>T transition (exon1) leading to a p.R69C substitution, 
identified in patient MBC, is located in the first intra-cytoplasmic loop. Both mutation 
replace important amino acid residues that interfere with protein folding (class II 
mutations). 
The mutation frequency of this Portuguese sample is 4,16% (2/48) which is not 
concordant with earlier studies in other Caucasian populations. This is probably due to 
the geographic isolation for many centuries and high consanguineous rates in our 
population. 
Complete clinical assessment disclosed typical autosomal dominant cases but 
with early-onset of symptoms, which might be related to the position and function of the 
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amino acid replaced in the protein. Differences related to rhythms of progression of the 
disease could be explained by differences in the genetic background or environmental 
factors.  
RESUMO 
A distrofia de bastonetes e cones é um grupo heterogéneo de doenças genéticas 
da retina que são caracterizadas pela perda progressiva dos fotoreceptores, geralmente 
provocando graves perturbações da visão. É uma das doenças hereditárias da retina mais 
frequentes com um conjunto único de características clínicas que a tornam uma doença 
complexa associada a diferentes padrões de hereditariedade. As mutações no gene da 
rhodopsina (RHO) são, provavelmente, a causa mais frequente de Retinopatia 
Pigmentada autossómica dominante, contudo, a prevalência na população Portuguesa 
não está estabelecida. 
Neste estudo, utilizamos a sequenciação directa para analizar os cinco exões e 
regiões intrónicas adjacentes do gene da rodopsina (RHO) em 48 probandos portugueses 
com diferentes formas de RP não ligadas ao cromossoma X. 
Identificámos duas novas mutações missense no gene da rodopsina em 2 dos 48 
probandos testados; a transição c.180 T>C (exão 1) que provoca uma substituição 
p.Y60H, identificada no paciente AAV, está localizada na extremidade citoplasmática 
do primeiro domínio transmembranar; enquanto, a transição c.207 C>T (exão1) que 
provoca uma substituição p.R69C, identificada no paciente MBC, está localizada na 
primeira loop intra-citoplasmática. Ambas as mutações provocam a substituição de 
aminoácidos importantes que interferem com a estrutura terciária da proteína (mutações 
de classe II).  
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A prevalência de mutações na amostra de Portugueses é 4,16% (2/48), sendo 
inferior a estudos anteriores em populações caucasianas. Isto, provavelmente, é devido 
ao isolamento geográfico durante vários séculos e a uma alta taxa de consanguinidade 
na nossa população. 
A avaliação clínica completa revelou casos típicos de retinopatia pigmentada 
autossómica dominante, contudo com um início precoce dos sintomas, o que pode estar 
ligado à posição e função dos aminoácidos substituídos na proteína. As diferenças 
relacionadas com o ritmo de progressão da doença podem ser explicadas por diferenças 
no background e factores ambientais.  
KEY WORDS 
Autosomal dominant RP (adRP), Genotype/phenotype correlation, Missense 
mutations, Photoreceptors degeneration, Rhodopsin gene (RHO), Rod-cone dystrophies 
(RCD), Portuguese population 
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INTRODUCTION 
Rhodopsin is a G protein-coupled receptor (GPCR) - family A [1], with a seven 
α-helical transmembrane architecture, that is covalently bound via a protonated Schiff 
base to the light sensitive chromophore 11-cis-retinal, which is the only light-sensitive 
protein in the visual transduction cascade.  [2-3] 
The importance of rhodopsin arises from its primary role in vision (initiation of 
phototransduction cascade). It constitutes up to 85% of the total amount of protein in the 
rod outer segment (ROS) [4] and is present both in the plasma membrane and in the 
lamellar sides of the disks.  
Using somatic cell hybrid studies, Nathans and Hogness assigned the human 
Rhodopsin gene (RHO, MIM #180380), which consists of five exons, to 3q21-ter. [5] 
Mutations in the RHO were first described in 1990. [6-7] 
Although there are reports of autosomal recessive Retinitis Pigmentosa (arRP) 
[8-11], congenital stationary night blindness (CSNB) [12-15] and retinitis punctata 
albescens [16], almost all mutations in the RHO cause autosomal dominant RP (adRP). 
[17] In the adRP, the second most frequent mode of inheritance of RP (15% to 20%), 
20-25% of families have mutations in rhodopsin. [17] 
So far, over 120 mutations have been found in the RHO gene in association with 
RP. [17] They are located in all three domains of rhodopsin, namely the intradiscal, the 
transmembrane and the cytoplasmic domains.     
Soon after the identification of mutations in RHO, additional studies with 
transgenic mice indicated that defective folding (class II) [18-19] and transport (class I) 
[20-21] of rhodopsin to the membrane are the primary defects in adRP. [22-26]   
RP belongs to the group of pigmentary retinopathies, a generic name that covers 
all retinal dystrophies presented with a loss of photoreceptors and retinal pigment 
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deposits. [27] The word ‘‘retinitis’’ is a misnomer because retinal inflammation does 
not play a prominent role in the disease’s pathophysiology [28] and the word 
"pigmentosa" refers to an associated discoloration of the retina, which is detectable on 
eye examination.  
RP is the leading cause of inherited retinal degeneration - associated blindness 
worldwide [28-33] with a prevalence approximately 1 in 3,000 to 1 in 5,000 individuals 
[28, 30-33], affecting approximately 1.5 million people. [32, 34-35]    
The most common form of RP is a rod-cone dystrophy (RCD), characterized by 
the primary degeneration of rods followed by a secondary loss of cone sensitivity in the 
later stages. Patients typically present a history of night blindness followed by a mid-
peripheral visual field loss. In the later stages of the disease, cone degeneration becomes 
more evident with the loss of central vision acuity and color vision defects. RP is 
usually non-syndromic but there are also many syndromic forms, the most frequent 
being Usher syndrome. [36-37]  
Degeneration of photoreceptors associated with RP, although stimulated by 
various processes, is primarily genetically programmed. [28-34] Despite reports of 
families where the RP phenotype follows a non-mendelian inheritance pattern [38-42] 
the vast majority are inherited as mendelian traits. Most cases are monogenic, but the 
disease is nevertheless very heterogeneous genetically; and most genes involved in the 
disease are linked to only one form of inheritance (exceptions, mutation NRL, RP1 and, 
exceptionally, RHO). [43] 
AdRP are usually the mildest forms (slowest progression), with some cases 
starting after the age of 50 [44], however severe disease can also appear. [45] Most 
pedigrees show complete penetrance, and yet, adRP can vary greatly from individual to 
individual even within the same pedigree. [44] 
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Objective measures of photoreceptor sensitivity, such as electroretinogram, are 
much more reliable than symptoms for diagnosis of RP and grading its severity.  
In this study, we propose to identify prevalence of RHO mutations in Portuguese 
patients with non-X linked forms of RP. Then, perform a complete clinical assessment 
including novel techniques for better structural and functional assessment of retinal 
degeneration with special care given to the study of rod and cone photoreceptors. 
Finally, identify potential genotype/phenotype correlation of patients with different 
mutations on the RHO gene. 
POPULATION AND METHODS 
Patients with RP/RCD were collected from our Center of Excellence for 
Hereditary Eye Diseases from de Department of Ophthalmology, University Hospital of 
Coimbra, between 1995 and 2010. A total of 48 probands with adRP, arRP, unknown 
patterns of inheritance, and cases without a family history (isolated) were collected 
during this period.  
Detailed phenotypic characterization was performed, including family history, 
geographic provenance, best-corrected visual acuity (BCVA), slit-lamp examination, 
fundus examination using a non-contact 78 D lens. Fundus images were acquired in 
accordance to the International accepted guidelines using a Zeiss fundus camera with 
VISUPAC
TM
 Digital Imaging System (Carl Zeiss, Meditec, Jena, Germany) and a Pan-
Retinal camera (OptomapR) (Optos plc, Dunfermline, Scotland, UK). Visual fields 
were assessed using a Humphrey Visual Field Analyzer i-Series (Carl Zeiss Ophthalmic 
Systems Inc, Dunblin, CA, USA), in accordance with the manufacturer’s guidelines. 
Ganzfeld electroretinography (ERG) was performed in accordance with the ISCEV 
(International Society for Clinical Electrophysiology of Vision) guidelines. Clinical 
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assessment was completed with fundus autofluorescence imaging and optical coherence 
tomography (OCT) (HRAII and Spectralis OCT, respectively; Heidelberg Engineering, 
Dossenheim, Germany).  
Peripheral blood samples with EDTA anticoagulant were collected from each 
patient. Genomic DNA was extracted using an Automated Extractor (BioRobots EZI, 
Qiagen, Hilden, Germany). The exons of the RHO gene, including the intron-exon 
boundaries, were PCR-amplified with previously described primers. [46]Sequencing 
reactions were performed using the 4-dye terminator cycle sequencing ready reaction kit 
(Big Dye DNA sequencing kit, Applied Biosystems, Foster City, CA, USA). Sequence 
products were resolved in a ABI Prism 3130 (Applied Biosystems).  
This study was approved by the local ethics committee and followed the tenets 
of the Declaration of Helsinki. Informed consent was obtained from the participating 
individuals or their guardians prior to the collection of clinical data and genomic 
samples.  
RESULTS 
We screened the major gene for adRP, the RHO gene, for underlying rod-cone 
dystrophy by direct sequencing of the coding exons and flanking intronic regions in 
each proband. Two novel RHO missense mutations were identified, representing a c.180 
T>C transition (exon 1) leading to a p.Y60H substitution (Fig. 1.1) and a c.207 C>T 
transition (exon1) leading to a p.R69C substitution (Fig. 1.2) in 2 of the 48 unrelated 
tested probands. Thus, the overall allele mutation frequency of this Portuguese sample 
is 4,16% (2/48) (Table I). Both mutations affect highly conserved amino acid residues 
and are not present in the healthy control population.  
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Figure 1.1 - Direct sequencing of the coding region of exon 1, patient AAV. A- Heterozygous missense 
mutation (TAC60CAC); B- Normal sequence around codon 60 of exon 1. 
 
 
 
 
Figure 1.2- Direct sequencing of the coding region of exon 1, patient MBC. 1. A- Heterozygous missense 
mutation (CGC69TGC); B- Normal sequence around codon 69 of exon 1. 
 
 
 
Codon 60 – T>C Heterozygous  
(Y60H) Exon 1 
Codon 60 – Normal sequence  
A B 
Codon 69 – T>C Heterozygous  
(R69C) Exon 1 
Codon 69 – Normal sequence  
A B 
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Table I- Sequence variation detected in RHO of patients. 
 
 
 
 
Both probands with heterozygous RHO mutations have clinical symptoms and 
signs of RP. They were available for clinical investigation, and the examination results 
are summarized in Table II.   
AAV is a 57 year-old single male, born to non-consanguineous parents and no 
past family history of retinopathies (Fig. 2). His first disease symptoms started around 
age 7 with complaints of night blindness. Changes in the visual field were first noted 
during adolescence, with slow constriction of visual fields in parallel with progressive 
loss of vision. Photophobia became a problem after the fourth decade of life. At present 
his best corrected visual acuity is light perception with good projection for both eyes. 
Ophthalmic examination disclosed abolished pupillary reflexes, absence of 
nystagmus, normal ocular motility with orthotropia for near and distance. Slit-lamp 
examination revealed bilateral pseudophakia with posterior chamber intra-ocular lens 
(IOL) and transparent posterior capsules. Dilated fundus examination (Fig. 3) depicted a 
pale optic disc, extremely narrow retinal vessels, scattered atrophy of the retinal 
pigment epithelium (RPE) with macular involvement and bone spicules distributed in 
the mid- and far periphery. This clinical picture is symmetrical in both eyes.   
Complete phenotypical characterization included spectral-domain OCT (Fig. 4) 
that revealed significant disorganization of the RPE/photoreceptor interface, granular 
deposits in the outer retina and thinning of the neurosensory retina. Autofluorescence 
imaging (Fig. 5) demonstrated a macular hyperfluorescent ring surrounded by globular 
Variation Effect Prediction Frequency 
in patients 
Note 
c.180 T>C p.Y60H Damaging 1/48 Novel 
c.207 C>T p.R69C Damaging 1/48 Novel 
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areas of complete RPE atrophy, very thin retinal vessels and relative hypofluorescence 
in the perifoveal area. Ganzfleld ERG was completely flat. We did not perform 
multifocal ERG in this patient. Very limited visual acuity did not allow the use of 
Humphrey Visual field analysis. 
 
 
 
Figure 2- Pedigree of patient AAV who 
carries a c.180T>C transition leading to a 
p.Y60H substitution (simplex RP case). 
Patients II-1(AAV) is heterozygous for the 
mutation; unaffected family members are   
I-1 and I-2.  
 
 
 
 
 
 
 
 
 
 
Figure 3- OptomapR images showing 200º fundus pictures. 3A (Right eye) Significant optic pallor, thin 
vessels, densely pigmented mid-periphery and scattered pigment bone spicules in the far periphery.  
Relative preservation of the inferior-nasal mid-periphery (less pigmented) is observed. 3B (Left eye) a 
symmetrical picture is observed for the contralateral fundus. 
3A) 3B) 
57 
I 
II 
I - 1 I - 2 
II - 1 
Male   Proband 
Female  Affected 
Unaffected  Deceased 
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Figure 4- Spectral-domain OCT images line passing through the central macular area. Relative 
preservation of retinal thickness in the perifovea contrast with significant peripheral atrophy (macula). 
Disorganization of outer retinal layers. Inset 4A right eye; inset 4B left eye.   
 
 
 
 
 
 
 
 
 
 
 
Figure 5- Auto-fluorescence images. 5A: right eye; 5B: Left eye. Macular hyperfluorescent ring 
surrounded by globular areas of complete RPE atrophy, very thin retinal vessels and relative 
hypofluorescence in the perifoveal area. Left eye displays a thicker and more hyperfluorescent ring. 
 
 
4A) 
 
4A) 
 
4B) 
 
5A) 
 
5B) 
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MBC is a 59 year-old married male, born to non-consanguineous parents. 
Family history showed that his two elder brothers also had RP, but the youngest was 
unaffected; by questionnaire, his parents do not seem to be affected and have distinct 
geographical origin (Fig. 6). Symptoms included early-onset night vision disturbances 
(night blindness before age 10), constricted visual fields by confrontation and 
asymmetric decreased vision starting at the third decade of life. Photophobia became a 
problem after the fifth decade of life representing a mild to moderate impairment. At 
present his best corrected visual acuity is OD (right eye): 6:10 and OS (left eye): 3:10. 
Complete ophthalmic assessment disclosed reduced pupillary reflexes, absence 
of nystagmus, normal ocular motility with orthotropia for near and distance. Slit-lamp 
examination revealed bilateral pseudophakia with posterior chamber IOL and 
transparent posterior capsules. Dilated fundus examination (Fig. 7 and 8) reveals patchy 
and asymmetrical areas of chorioretinal atrophy, optic disc pallor, narrow retinal blood 
vessels and bone spicule deposits distributed in the mid- and far periphery. This clinical 
picture is symmetrical in both eyes. 
Further phenotypical characterization included spectral-domain OCT (Fig. 9) 
that revealed significant disorganization of the outer and inner layers of the 
neurosensory retina, a thick posterior hyaloid membrane/fibroglial proliferation that 
eliminates the typical central foveal pit and granular deposits in the outer retina. The 
loss of the outer retinal structures in atrophic areas is associated with increased deep 
backscatter and subretinal pseudocystic lesions that seem to correspond to vascular 
structures. Autofluorescence imaging (Fig. 10) revealed areas of granular RPE clumps 
with hyperautofluorescence interspersed with globular atrophic areas of RPE and outer 
retina. No typical hyperfluorescent ring was detected in this patient. Ganzfleld ERG was 
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completely flat. We did not perform multifocal ERG in this patient. Humphrey Visual 
field analysis demonstrated constricted visual field, less than 5º centrally (Fig.11). 
  
 
 
Figure 6- Pedigree of patient who carries a 
c.207 C>T transition leading to a p.R69C 
substitution in patient with presumed 
autosomal dominant RP. Patients II-1 
(MBC) is heterozygous for the mutation;  
II-1 and II-2 are affected and unaffected 
family members are I-1, I-2 and II-4.  
 
 
 
 
 
 
 
 
 
 
 
Figure 7- Fundus photography: 7A: Right eye: optic atrophy, significantly thin retinal vessels, patch 
atrophy of RPE; beaten bronze macula; peripheral pigmented bone spicules. 7B Left eye: same aspect; 
noteworthy the fact that there is paravascular pigment clumping along the inferior temporal arcade and 
also the superior temporal arcade. 
 
7B) 
 
7A) 
 
59 
I 
II 
II - 1 
I - 1 I - 2 
II - 2 II - 3 II - 4 
Male   Proband 
Female  Affected 
Unaffected  Deceased 
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Figure 8- OptomapR images showing 200º fundus pictures. 8A (Right eye) Optic atrophy, thin vessels, 
pigmented mid-periphery and scattered pigment bone spicules in the far periphery. 8B (Left eye) a 
symmetrical picture is observed for the contralateral fundus. 
 
 
 
 
 
 
 
 
Figure 9- Spectral domain OCT. 9A (Right eye) and 9B (Left eye) revealed significant disorganization of 
the outer and inner layers of the retina, a thick posterior hyaloid membrane/fibroglial membrane, no 
central foveal pit and granular deposits in the outer retina. Sub-RPE increased deep backscatter and 
subretinal pseudocystic lesions correspond to choroidal vascular structures. 
 
 
 
8A) 
 
8B) 
 
9A) 
 
9B) 
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Figure 10- Auto-fluorescence images. Right (10A) and left (10B) eyes: areas of granular 
hyperfluorescent RPE clumps surrounded by globular atrophic areas of RPE and outer retina. 
 
 
 
 
 
 
 
 
Figure 11- Humphrey visual field (10/2). 11A: Right eye; 11B: Left eye: constricted visual field, less 
than 5º centrally (Fig.11). 
 
10A
) 
 
10B
) 
 
11A) 
 
11B) 
 
20 
 
Table II- Clinical information from individuals with RHO variations. 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: M – Male; AD – Autosomal dominant; LP- Light perception; VF – Visual Field
ID Variations Gender Age  
(yrs) 
Age at 
onset 
Inheritance First 
symptom 
BCVA Fundus 
changes 
ERG 
responses 
(Ganzfeld) 
Humphrey 
Visual Field 
Analysis 
Rod Cone 
AAV c.180 T>C M 57 7 Simplex case Night 
Blindness 
OD: LP 
with good 
projection 
OS: LP 
with good 
projection 
RP; optic 
nerve 
atrophy, 
narrow 
vessels; 
RPE 
atrophic 
changes 
Flat Flat Not 
recordable 
MBC c.207 C>T M 59 50 Presumed AD Night 
Blindness 
OD: 6/10 
OS: 3/10 
RP; optic 
nerve 
atrophy, 
narrow 
vessels; 
RPE 
atrophic 
changes 
Flat Flat Constricted 
VF, less than 
5º centrally 
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DISCUSSION 
The present study provides a useful clue regarding the frequency of RHO 
mutations in the Portuguese population. The genetic screening reported here has 
identified two novel RHO missense mutations in 2 of the 48 unrelated tested probands. 
The c.180 T>C transition (exon 1) leading to a p.Y60H substitution, identified in patient 
AAV, is located at the cytoplasmic end of the first transmembrane domain, whereas the 
c.207 C>T transition (exon1) leading to a p.R69C substitution, identified in patient 
MBC, is located in the first intra-cytoplasmic loop (Fig. 12).  
 
 
Figure 12- Schematic Model of human rhodopsin showing the locations of mutations described in 
rhodopsin, reported to date. Two novel mutations reported here are identified with arrows (adapted from 
Preising 07.2000). 
 
Most of the rhodopsin mutations identified to date in subjects with adRP have 
been found in only one or just a few families. [6-7, 22, 47-50] 
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Although RHO is the first gene implicated [6-7] and probably the most studied 
gene in RP, the great number of rare mutations suggests that many additional mutations 
in the rhodopsin gene remain to be discovered. 
The finding of 2 novel clinically significant RHO mutations among 48 (2/48, 
4,16%) probands is not concordant with earlier estimates of 16% to 28,5% of frequency 
among caucasians with adRP. [47, 49, 51-52] However, there is strong evidence for 
ethnic variations in the mutation frequency of RHO [53-56], as it has been observed 
with other genetic eye diseases, namely Leber Congenital Amaurosis; this could be the 
result of a relative geographic isolation for many centuries or due to the high 
consanguineous rate in our population and the fact that RHO gene mutations are 
primarily related to AD forms of RP. Although we are dealing with a relatively small 
patient population, it would be expected to find a higher percentage of mutations. 
Both mutations affect highly conserved amino acid residues and are not present 
in the healthy control population. Some insight into possible mechanisms responsible 
for the ensuing retinal degeneration may be derived from considerations regarding the 
amino acids affected by these mutations. 
The c.180 T>C transition (exon 1), leads to a substitution of a tyrosine, which is 
an aromatic amino acid with nonpolar and hydrophobic characteristics, for a histidine, 
which is a basic amino acid with polar (positively charged) and hydrophilic 
characteristics, might alter drastically the structure of the protein and the stability in the 
bilayer lipid membrane. Histidine has quite unique structure and functional properties 
sharing no resemblance with other amino acids. It is rather ambiguous whether it prefers 
to be buried in the protein core or exposed to solvents. Also, histidine is the most 
common amino acid in protein functional centers and binding sites, which could explain 
why the change may potentially render inadequate rhodopsin activity. 
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The c.207 C>T transition (exon1), leads to a substitution of an arginine, which is 
a basic amino acid with polar (positively charged) and hydrophilic characteristics, for a 
cysteine, which is a neutral and small amino acid, probably disturbing the structure of 
the first intradiscal loop and consequently the tertiary structure of the mutant rhodopsin. 
Cysteine is known to be frequently involved in disulphide bonds that stabilize the 
protein structure, especially important in extracellular domains; however, in this case it 
may still be involved in the formation of disulfide bonds and/or protein interactions. In 
the intracellular environment, cysteines may still play a key structural role. Their 
sulfydryl side-chain is excellent for metal-binding, such as zinc, thus compromising 
protein function. 
According to disease mechanisms described in adRP [57], the novel mutations 
described here, belong to class II (defective protein folding) the most common in adRP 
mutations. Class I mutants, affecting the c-terminal region, fold normally in cell cultures 
but are not correctly transported into the outer segments in vivo. [57] Bioinformatic 
analysis and crystallography studies give further insight into the functional 
consequences of amino acid substitutions. 
To our knowledge, only three mutations were identified nearby. The p.Thr58Arg 
[58-59] (Fig.12), a cytosine-to-guanine (C-to-G) transversion mutation in the second 
nucleotide of codon 58 of the RHO gene, causing a substitution of the amino acid 
arginine for a threonine, showed regional predilection for pigmentary changes in the 
inferior and inferonasal quadrants of the retina, as well as visual scotomas 
predominantly in the superior hemifields (sector RP). This clearly differs from the 
phenotype observed in our affected probands.  
The p.Gln64ter mutation (Fig.12) [60] represents a nonsense mutation that is 
able to cause adRP, suggesting that synthesis of a rhodopsin fragment consisting of the 
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first 63 amino acids damages the rod photoreceptors. Cellular damage could result from 
disruption of the lipid bilayer structure or from interference with the folding or transport 
of other proteins. 
The in-frame 12-bp deletion of codons 68 to 71 [48] occurs in the cytoplasmic 
loop connecting the first and second transmembrane helices (Fig. 12). This is the most 
conserved region on the cytoplasmic surface and has been suggested to be a point of 
interaction with cytoplasmic proteins. [61] However, it seems possible that the removal 
of these amino acids has an effect on protein folding in addition to any functional 
significance this region may have in the signal transduction pathway.    
Rhodopsin mutations have been reported in association with other retinal 
phenotypes.  Autosomal recessive Retinitis Pigmentosa (arRP) [8-11] is caused by 
mutations in the cytoplasmic and extracellular domains, what might suggest that they 
have a more damaging effect compared with mutations in the transmembrane domains. 
Congenital stationary night blindness (CSNB) [12-15] has also been described, as the 
result of mutations in the extracellular end of the second and seven transmembrane 
domains, strengthening the hypothesis described above. The two novel mutations 
described here, are located in the cytoplasmic end of the first transmembrane domain 
and in the first intracytoplasmic loop; this may underlie the early observed disease onset 
in our probands. 
Suspicion of autosomal dominant pattern of inheritance usually occurs in the 
presence of mild sporadic cases [27]. In 10 to 40 percent of all cases of retinitis 
pigmentosa, only one person in a family is affected - simplex case. It can be difficult to 
determine the inheritance pattern in those cases because affected individuals may have 
no affected relatives or may be unaware of other family members with the disease. 
Simplex cases can also result from a new gene mutation that is not present in other 
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family members. Multiplex cases correspond to 2 or more affected family members 
(typically siblings) who have no pre-existing family history, which seems to be the case 
of patient MBC. Segregation analysis is still pending to confirm the etiology of our 
finding.  
Although the typical manifestations present between adolescence and early 
adulthood, the age of onset has been documented to range from infancy to adulthood 
[62]. Due to the remarkable variation in how aware individuals are of their visual loss, 
the age of onset of symptoms is an imprecise measure of disease severity and gives little 
or no indication of when photoreceptor degeneration actually begins. [43]  
Both probands report early-onset night vision disturbances accompanied by 
progressive loss of peripheral visual field. Photophobia became a problem after several 
years. There is no history of consanguinity or retinopathies. Clinically, they presented 
typical features of RP, including retinal vessels attenuation, bone spicule deposition, 
and a waxy appearance of the optic disc.  Usually early-onset and severe forms of RP 
with myopia in male are associated with X-linked RP (XLRP). [27] Perhaps, the 
position of the substituted amino acids in the protein, and the side chain polarity of the 
substituted amino acids may explain the similarity of phenotypes.  
AdRP, in most cases, is a long lasting disease that typically evolves over several 
decades with good overall long-term prognosis. Even at terminal stages, the disease 
progression remains slow. [27] The phenotypic variability seen between probands at age 
50 could be explained by differences in genetic background or by environmental 
factors, even though both of them are of European decent and have comparable 
lifestyles.  
This study contributed to emphasize the importance of RHO mutation screening 
in patients with RCD, since we identified two novel missense mutations. Also it gives 
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an overview of its prevalence in a Portuguese population. It was possible to attest the 
phenotypic variability associated with rhodopsin mutations and the need to improve our 
understanding of disease mechanisms to offer genetic counseling. 
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